Evidence map›Paper›PMID 30311408›Full record

ArticleCNS neuroscience & therapeutics2019

Integrated profiling identifies caveolae-associated protein 1 as a prognostic biomarker of malignancy in glioblastoma patients.

Qing Guo, Ge-Fei Guan, Wen Cheng, Cun-Yi Zou, Chen Zhu, Peng Cheng, An-Hua Wu

Open access · bronzeAbstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Targeting Immunometabolism in Glioblastoma.Frontiers in oncology · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Qing GuoDepartment of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.
Ge-Fei GuanDepartment of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.
Wen ChengDepartment of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.
Cun-Yi ZouDepartment of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.
Chen ZhuDepartment of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.
Peng ChengDepartment of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.ORCID 0000-0003-0626-7040
An-Hua WuDepartment of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.ORCID 0000-0002-3402-1884
First Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsGlioblastoma (GBM) is a lethal disease of the central nervous system with high mortality, and novel therapeutic targets and strategies for GBM are urgently needed. Caveolae-associated protein 1 (CAVIN1) is an essential caveolar component-encoding gene and has been poorly studied in glioma. To this end, in this study, we evaluated CAVIN1 expression in glioma tissue as well as the correlation between CAVIN1 expression and prognosis in glioma patients using the data collected from clinical samples or from the Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), Rembrandt, and Gene Expression Omnibus (GEO) data sets.

methodsSurvival analysis was performed with the Kaplan-Meier curve and log-rank test. The predictive role of CAVIN1 in progressive malignancy in glioma was evaluated by using a receiver operator characteristic (ROC) curve. Gene ontology (GO), Gene set enrichment analysis (GSEA), and gene set variation analysis (GSVA) methods were used to interpret the functions of CAVIN1 in GBM.

resultsCAVIN1 expression was elevated in GBM compared with that in low-grade glioma and nontumor brain samples and was correlated with unfavorable outcomes in glioma patients. Additionally, CAVIN1 could serve as an independent predictive factor for progressive malignancy in GBM. Furthermore, CAVIN1 was associated with disrupted angiogenesis and immune response in the tumor microenvironment of GBM.

conclusionsWe identified CAVIN1 as a prognostic biomarker and potential target for developing novel therapeutic strategies against GBM.

Indexed as

Biomarkers, TumorGene ExpressionGlioblastomaHumansPrognosisRNA-Binding ProteinsSurvival AnalysisBiomarkers, TumorCAVIN1 protein, humanRNA-Binding Proteinsbrain neoplasmsCAVIN1gliomaprognosis

Identifiers

PMID30311408
PMCPMC6488874
OpenAlexW2896671924

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.